Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Nov 05, 11:27 PMUSPH posts strong quarter as hospital affiliations lift pricing and 2026 EBITDA guidance of $102–$106 million reaffirmed
Index
RUT
Market Cap
1.45B
Enterprise Value
2.13B
Income
2.56M
Sales
812.20M
Book/sh
30.06
Cash/sh
1.67
Employees
7294
IPO
May 28, 1992
P/E
574.13
Forward P/E
28.84
PEG
2.40
P/S
1.79
P/B
3.23
P/C
58.28
P/FCF
22.26
EV/EBITDA
20.80
EV/Sales
2.62
Quick Ratio
1.27
Current Ratio
1.27
Debt/Eq
0.86
LT Debt/Eq
0.75
Option/Short
Yes / Yes
EPS (ttm)
0.17
EPS next Y
3.37
EPS next Q
0.91
EPS this Y
8.37%
EPS next Y
18.27%
EPS next 5Y
12.00%
EPS past 3/5Y
-14.24% -10.50%
Sales past 3/5Y
12.19% 13.05%
EPS Y/Y TTM
-92.59%
Sales Y/Y TTM
11.32%
EPS Q/Q
-56.45%
Sales Q/Q
8.47%
Insider Own
2.57%
Insider Trans
0.21%
Inst Own
109.44%
Inst Trans
3.97%
ROA
0.21%
ROE
0.54%
ROIC
0.33%
Gross Margin
17.45%
Oper. Margin
9.85%
Profit Margin
0.32%
SMA20
11.93%
SMA50
16.11%
SMA200
26.56%
Trades
Shs Outstand
14.92M
Shs Float
14.54M
52W High
100.98 -3.74%
52W Low
58.19 67.04%
Volatility
3.83% 3.41%
ATR (14)
3.43
RSI (14)
74.33
Beta
1.07
Rel Volume
0.00
Avg Volume
183.15K
Volume
0
Perf Week
12.28%
Perf Month
17.16%
Perf Quarter
21.42%
Perf Half Y
64.75%
Perf YTD
24.47%
Perf Year
10.39%
Perf 3Y
15.02%
Perf 5Y
-10.78%
Perf 10Y
75.14%
Prev Close
97.20
Price
97.20
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$101.83
Implied Upside
+4.8%
Analysts8incl. previous ratings
Rating Distribution7 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 13, 2026Reiterated
BBarrington Research
Outperform$103 → $90-7.4%
Mar 10, 2026Resumed
JEF logoJJefferies
Buy$102+4.9%
Sep 18, 2025Resumed
JPM logoJJP Morgan
Overweight$110+13.2%
Dec 16, 2024Upgrade
BAC logoBBofA Securities
Neutral → Buy$100 → $115+18.3%
Dec 16, 2024Initiated
JJMP Securities
Mkt Outperform$113+16.3%
Oct 07, 2024Downgrade
BAC logoBBofA Securities
Buy → Neutral$114 → $90-7.4%
Sep 22, 2023Initiated
JPM logoJJP Morgan
Overweight$108+11.1%
Jun 30, 2023Initiated
BAC logoBBofA Securities
Buy$138+42.0%
Dec 14, 2021Upgrade
CCJS Securities
Market Perform → Market Outperform$120+23.5%
Aug 06, 2021Reiterated
BBarrington Research
Outperform$130 → $139+43.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Minan Peter FrancisDirectorSep 11 '26Buy79.0054163,217Sep 14 04:17 PM
Minan Peter FrancisDirectorJun 12 '26Buy66.501583,212Sep 14 04:17 PM
Minan Peter FrancisDirectorJun 08 '26Buy63.1449231,0652,923Jun 10 06:36 PM
Minan Peter FrancisDirectorJun 09 '26Buy61.5028817,7123,211Jun 10 06:36 PM
REEVE GRAHAM D.COOMar 11 '26Sale78.8666252,20530,078Mar 12 04:41 PM
Graham ReeveaffiliateMar 11 '26Proposed Sale78.761,964154,688Mar 11 02:31 PM
Binstein RichardEVP Gen'l Counsel & SecretaryMar 06 '26Sale81.643,000244,92024,867Mar 09 04:28 PM
Graham ReeveCOOMar 06 '26Proposed Sale82.241,808148,687Mar 06 04:28 PM
Richard BinsteinAffilitateMar 06 '26Proposed Sale81.643,000244,905Mar 06 12:40 PM
REEVE GRAHAM D.COONov 24 '25Sale71.0174352,76020,740Nov 25 04:08 PM
Gilmartin Kathleen ADirectorNov 20 '25Buy69.004,000276,00024,786Nov 24 04:09 PM
Graham D. ReeveAffiliateNov 21 '25Proposed Sale71.0174352,762Nov 24 03:46 PM
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics, which provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. It operates through the Physical Therapy Operations and Industrial Injury Prevention Services segments. The Physical Therapy Operations segment consists of physical therapy and occupational therapy clinics that provide pre-and postoperative care and treatment for orthopedic related disorders, sports-related injuries, preventive care, rehabilitation of injured workers and neurological injuries. The Industrial Injury Prevention Services segment includes onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The company was founded in 1990 and is headquartered in Houston, TX.
CEO & ChairmanMr. Christopher J. Reading
President & COOMr. Eric Joseph Williams
Executive VPMr. Richard S. Binstein
P.T.Mr. Graham D. Reeve M.B.A.
CEO of Metro & DirectorMr. Michael G. Mayrsohn